Its looking like a poor end to 2025 for investors in two biotechnology companies that on Monday reported surprisingly disappointing trial results for a treatment for a rare bone disease.
Shares of b… [+182 chars]
These biotech stocks are getting hammered by shocking brittle-bone treatment study results - MarketWatch
Shares of both Ultragenyx and Mereo BioPharma were seeing record selloffs after disappointing trial results for setrusumab
By:Tomi Kilgore
Source:MarketWatch
Published:
Related News
Stock Market News for Jan. 23, 2026: Dow Drops; Intel Stock Slides - The Wall Street Journal
Dollar tumbles against the yen, while gold prices hit record
The Wall Street Journal•Heard Editors, Paulo Trevisani, WSJ Staff, Hannah Erin Lang, Dean Seal, Dan Gallagher, Ryan Dezember, David Benoit, Xavier Martinez, Jacob Passy, Matt Grossman
Dow Jones Futures: Tesla, Microsoft, Meta, Apple Lead Earnings Wave; What To Do Now - Investor's Business Daily
The major indexes are all above key levels, while small caps are at record highs.
Investor's Business Daily
Analyst sends blunt 3-word warning on Intel stock after earnings - thestreet.com
Here’s what could be next for Intel stock.
TheStreet•Silin Chen